Table 2 Relationship between adverse events and everolimus blood concentration
|  | Total (n = 10) | Everolimus blood concentration just before discontinuation or dose reduction (ng/mL) | ||||
|---|---|---|---|---|---|---|
≤ 15.3 (n = 5) | >  15.3 (n = 5) | |||||
| Â | All grades | Grade 3 or 4 | All grades | Grade 3 or 4 | All grades | Grade 3 or 4 |
Number of patients | ||||||
 Any event | 8 | 5 | 3 | 2 | 5 | 3 |
 Fatigue | 1 | 0 | 0 | 0 | 1 | 0 |
 Nausea | 1 | 0 | 0 | 0 | 1 | 0 |
 Vomiting | 1 | 0 | 0 | 0 | 1 | 0 |
 Mucosal inflammation | 5 | 0 | 2 | 0 | 3 | 0 |
 Diarrhea | 1 | 0 | 0 | 0 | 1 | 0 |
 Rash | 2 | 0 | 1 | 0 | 1 | 0 |
 Pneumonitis | 4 | 2 | 2 | 1 | 2 | 1 |
 Increased aspartate aminotransferase | 2 | 0 | 0 | 0 | 2 | 0 |
 Increased alanine transaminase | 2 | 0 | 0 | 0 | 2 | 0 |
 Increased alkaline phosphatase | 3 | 0 | 0 | 0 | 3 | 0 |
 Increased γ-glutamyltransferase | 1 | 1 | 0 | 0 | 1 | 1 |
 Leukopenia | 3 | 2 | 1 | 1 | 2 | 1 |
 Neutropenia | 2 | 0 | 1 | 0 | 1 | 0 |
 Thrombocytopenia | 2 | 0 | 0 | 0 | 2 | 0 |
 Anemia | 2 | 0 | 0 | 0 | 2 | 0 |
 Hypoalbuminemia | 1 | 1 | 0 | 0 | 1 | 1 |
 Hyperglycemia | 2 | 1 | 0 | 0 | 2 | 1 |